PDCD2L

Across TCGA pan-cancer cohorts, PDCD2L mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of PDCD2L’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PDCD2L mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PDCD2L is over-expressed in tumor.

CCRCC, HNSC, and LSCC are the cancer types where PDCD2L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PDCD2L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	+0.818	<.001	12	view →
HNSC	All	All	+0.201	<.001	11	view →
LSCC	Male	II,III,IV	+0.802	<.001	9	view →
LUAD	Female	II,III,IV	+0.469	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

PDCD2L–CCRCC

Open the CCRCC breakdown →